# HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

> **NCT05728619** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Recurrent Extensive Stage Small Cell Lung Carcinoma

## Interventions

- **DRUG:** HTMC0435
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05728619
- **Lead sponsor:** Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-03
- **Primary completion:** 2024-08
- **Final completion:** 2024-10
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728619, "HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05728619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*